Kips Bay Liquidates As Its Bypass Graft Device Shows Poorly In Study
This article was originally published in The Gray Sheet
The struggling Minnesota company made a last-ditch effort to complete the eMESH 1 trial of the eSVS Mesh device for coronary artery bypass graft surgery, but the firm, founded by device sector luminary Manny Villafana, has decided to give it up after the early results from the trial proved disappointing.
You may also be interested in...
The company is downsizing to keep its clinical trial for its eSVS Mesh product on track. It estimates it currently has enough funds to last it through the year, but cautions it may take months to gather patient follow-up data.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.